We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA, BPDCN 최초 표적 치료제 피베키맙 수니린 등록. 관해율 69.7%지만 위험 존재. 약물 및 결과에 대한 상세 분석.
